Patents by Inventor Xiaofei Liang

Xiaofei Liang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210312359
    Abstract: A method and device for scheduling automated guided vehicles, the method comprising: acquiring, based on a task for scheduling automated guided vehicles, information of a set of temporary parking points and information of automated guided vehicles (S101); calculating, based on the information of the set of temporary parking points and the information of automated guided vehicles, the number of missing vehicles at each temporary parking point in the set of temporary parking point (S102); selecting, based on the number of missing vehicles, a target temporary parking point from the set of temporary parking points, and scheduling the automated guided vehicles to be scheduled to the target temporary parking point (S103).
    Type: Application
    Filed: July 31, 2019
    Publication date: October 7, 2021
    Inventors: Xiaofei QI, Zhikang LIANG
  • Publication number: 20210277144
    Abstract: Provided is an anti-HER3 humanized monoclonal antibody. The antibody is bound with HER3 antigen, has high affinity and biological activity and low immunogenicity, and is stable in structure. The antibody can be used for preparing drugs for preventing or treating HER3-related diseases.
    Type: Application
    Filed: July 17, 2019
    Publication date: September 9, 2021
    Inventors: Aidong QU, Hongyuan LIANG, Fanhong XU, Aoxiang LI, Lina WU, Jingye ZHU, Jianhua QIU, Jin LU, Lin ZHANG, Xin ZHAO, Xiaofei SONG
  • Publication number: 20210206715
    Abstract: Disclosed are compounds of formulae: and pharmaceutically acceptable salts thereof, wherein the variables, R1, R2, R3, R4, R5, R6, R7, R11, R12, R13, R14, R15, R16, R17, n, and m are defined herein. These compounds are useful for treating Gram-negative bacteria infections. Also disclosed are methods of making these compounds.
    Type: Application
    Filed: March 19, 2021
    Publication date: July 8, 2021
    Applicants: Duke University, The University of North Carolina at Chapel Hill
    Inventors: Pei Zhou, Eric J. Toone, Robert A. Nicholas, Ramesh Gopalaswamy, Xiaofei Liang, Frank Navas, III
  • Patent number: 11034649
    Abstract: Disclosed are compounds of formulae: and pharmaceutically acceptable salts thereof, wherein the variables, R1, R2, R3, R4, R5, R6, R7, R11, R12, R13, R14, R15, R16, R17, n, and m are defined herein. These compounds are useful for treating Gram-negative bacteria infections. Also disclosed are methods of making these compounds.
    Type: Grant
    Filed: April 25, 2017
    Date of Patent: June 15, 2021
    Assignees: DUKE UNIVERSITY, THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL
    Inventors: Pei Zhou, Eric J. Toone, Robert A. Nicholas, Ramesh Gopalaswamy, Xiaofei Liang, Frank Navas, III
  • Publication number: 20200323850
    Abstract: The present invention relates to a kinase inhibitor, comprising a compound of Formula I or a pharmaceutically acceptable salt, solvate, ester, acid, metabolite or prodrug thereof. The present invention also relates to a pharmaceutical composition comprising the kinase inhibitor, and to uses and methods for using these compounds and compositions to inhibit the activity of wild-type FLT3, mutant FLT3-ITD, PDGFR? and/or PDGFR? kinase in a cell or a subject, as well as uses and methods of these compounds and compositions to preventing or treating kinase-associated conditions in a subject.
    Type: Application
    Filed: December 26, 2017
    Publication date: October 15, 2020
    Applicant: HEFEI INSTITUTES OF PHYSICAL SCIENCE, CHINESE ACADEMY OF SCIENCES
    Inventors: Qingsong LIU, Jing LIU, Xiaofei LIANG, Beilei WANG, Kailin YU, Zongru JIANG, Cheng CHEN, Chen HU, Wenchao WANG, Fengming ZOU, Qingwang LIU, Feng LI, Wenliang WANG, Li WANG
  • Patent number: 10550074
    Abstract: Disclosed are compounds of formulae: and pharmaceutically acceptable salts thereof, wherein the variables, R1, R2, R3, R4, R5, R6, R7, R11, R12, R13, R14, R15, R16, R17, n, and m are defined herein. These compounds are useful for treating Gram-negative bacteria infections. Also disclosed are methods of making these compounds.
    Type: Grant
    Filed: February 7, 2019
    Date of Patent: February 4, 2020
    Assignees: DUKE UNIVERSITY, THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL
    Inventors: Pei Zhou, Eric J. Toone, Robert A. Nicholas, Ramesh Gopalaswamy, Xiaofei Liang, Frank Navas, III
  • Publication number: 20190367446
    Abstract: Disclosed are compounds of formulae: and pharmaceutically acceptable salts thereof, wherein the variables, R1, R2, R3, R4, R5, R6, R7, R11, R12, R13, R14, R15, R16, R17, n, and m are defined herein. These compounds are useful for treating Gram-negative bacteria infections. Also disclosed are methods of making these compounds.
    Type: Application
    Filed: April 25, 2017
    Publication date: December 5, 2019
    Inventors: Pei Zhou, Eric J. Toone, Robert A. Nicholas, Ramesh Gopalaswamy, Xiaofei Liang, Frank Navas, III
  • Publication number: 20190169114
    Abstract: Disclosed are compounds of formulae: and pharmaceutically acceptable salts thereof, wherein the variables, R1, R2, R3, R4, R5, R6, R7, R11, R12, R13, R14, R15, R16, R17, n, and m are defined herein. These compounds are useful for treating Gram-negative bacteria infections. Also disclosed are methods of making these compounds.
    Type: Application
    Filed: February 7, 2019
    Publication date: June 6, 2019
    Inventors: Pei Zhou, Eric J. Toone, Robert A. Nicholas, Ramesh Gopalaswamy, Xiaofei Liang, Frank Navas, III